Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019046185) USE OF HIGH MOLECULAR WEIGHT POLYETHYLENE GLYCOL COMPOSITIONS TO RESTORE THE EFFICACY OF PEGYLATED THERAPEUTIC COMPOSITIONS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/046185 International Application No.: PCT/US2018/048126
Publication Date: 07.03.2019 International Filing Date: 27.08.2018
IPC:
A61K 47/10 (2017.01) ,A61K 47/30 (2006.01) ,A61K 47/50 (2017.01) ,A61K 47/60 (2017.01) ,A61P 37/00 (2006.01) ,C12N 15/88 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
06
Organic compounds
08
containing oxygen
10
Alcohols; Phenols; Salts thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
30
Macromolecular compounds
[IPC code unknown for A61K 47/50][IPC code unknown for A61K 47/60]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
87
Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
88
using micro-encapsulation, e.g. using liposome vesicle
Applicants:
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL [US/US]; 109 Church Street Chapel Hill, North Carolina 27516, US
Inventors:
LAI, Samuel; US
MCSWEENEY, Morgan; US
Agent:
MUELLER, Lisa V.; US
Priority Data:
62/550,84728.08.2017US
Title (EN) USE OF HIGH MOLECULAR WEIGHT POLYETHYLENE GLYCOL COMPOSITIONS TO RESTORE THE EFFICACY OF PEGYLATED THERAPEUTIC COMPOSITIONS
(FR) UTILISATION DE COMPOSITIONS DE POLYÉTHYLÈNE GLYCOL DE POIDS MOLÉCULAIRE ÉLEVÉ POUR RESTAURER L'EFFICACITÉ DE COMPOSITIONS THÉRAPEUTIQUES PÉGYLÉES
Abstract:
(EN) The present disclosure relates to methods of reducing accelerated blood clearance of at least one pegylated therapeutic composition in a subject suffering from a disease and in need of treatment. The methods involve administering at least one high molecular weight polyethylene glycol composition to a subject suffering from a disease. The administration of at least one high molecular weight polyethylene glycol composition can also be used to increase the circulation half-life of at least one pegylated therapeutic composition as well as restore the pharmacokinetics of the pegylated therapeutic composition in a subject having a high titer of anti-polyethylene glycol antibodies.
(FR) La présente divulgation concerne des procédés de réduction de la clairance sanguine accélérée d'au moins une composition thérapeutique pégylée chez un sujet souffrant d'une maladie et nécessitant un traitement. Les procédés comprennent l'administration d'au moins une composition de polyéthylène glycol de poids moléculaire élevé à un sujet souffrant d'une maladie. L'administration d'au moins une composition de polyéthylène glycol de poids moléculaire élevé peut également être utilisée pour accroître la demi-vie de circulation d'au moins une composition thérapeutique pégylée, ainsi que pour restaurer la pharmacocinétique de la composition thérapeutique pégylée chez un sujet présentant un titre élevé d'anticorps anti-polyéthylène glycol.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)